منابع مشابه
Bone loss: Epidemiology of bone loss
Bone loss occurs when the cellular events of bone formation are quantitatively larger than bone formation. This manuscript discusses the measurement of bone loss, occurrence in the population, risk factors and consequences of bone loss. Recent developments in bone mass measurement and biomarkers have improved our ability to assess bone loss. This process is a normal concomitant of ageing. There...
متن کاملBone Loss and Bone Size after Menopause
From the Departments of Orthopedics (H.G.A., O.J., M.K.K.) and Obstetrics and Gynecology (G.R.), Malmö University Hospital, Malmö, Sweden; and the Department of Orthopedic Surgery and the Biomechanics and Biomaterials Research Center, Indiana University, Indianapolis (C.H.T.). Address reprint requests to Dr. Ahlborg at the Department of Orthopedics, Malmö University Hospital, SE-205 02 Malmö, S...
متن کاملBone loss and bone size after menopause.
BACKGROUND Bone loss increases after menopause. However, bone strength also depends on structural characteristics such as bone size. Whether bone size increases as a result of periosteal apposition and whether a strength index accounting for both bone density and bone size might predict the risk of fracture better than bone density alone are unclear. METHODS Bone mass and the skeletal structu...
متن کاملCorrelation between lipid-lowering and bone-protective effects of eicosapentaenoic acid in rats with steroid-induced bone loss
This study was conducted to investigate the correlation between lipid-lowering and bone-protective effects of eicosapentaenoic acid on steroid-induced bonechanges in rats. Twenty-one male 10-week-old Wistar rats were divided into 3 groups (n = 7 each) and treated with 0.9% NaCl SC (group 1) or methylprednisolone 7 mg/kg SC once a week (group 2) or methylprednisolone 7 mg/kg SC once a week + eic...
متن کاملAromatase inhibitors and bone loss.
The aromatase inhibitors (AIs) anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are significantly more effective than the selective estrogen-receptor modulator (SERM) tamoxifen in preventing recurrence in estrogen receptor-positive early breast cancer. Aromatase inhibitors are likely to replace SERMs as first-line adjuvant therapy for many patients. However, AIs are associa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: COPD: Journal of Chronic Obstructive Pulmonary Disease
سال: 2008
ISSN: 1541-2555,1541-2563
DOI: 10.1080/15412550802374854